Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Developments in cancer vaccination.

Joanne Lysaght1, Stephen Todryk

  • 1Immune Regulation Research Group, Department of Biochemistry, Trinity College Dublin, Dublin 2, Ireland.

Current Opinion in Investigational Drugs (London, England : 2000)
|August 7, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cystic lesions and their role in pancreatic cancer risk stratification.

Translational oncology·2026
Same author

The insider's perspective: The intracellular complosome and immune cell dynamics in cancer.

Clinical and translational medicine·2026
Same author

FOXP3 is a favourable prognostic indicator in oesophageal adenocarcinoma.

Pathology, research and practice·2025
Same author

Measuring Human Memory B Cells in Autoimmunity Using Enzyme-Linked ImmunoSpot.

Biomolecules·2025
Same author

The multifactorial effect of obesity on the effectiveness and outcomes of cancer therapies.

Nature reviews. Endocrinology·2024
Same author

Complement is increased in treatment resistant rectal cancer and modulates radioresistance.

Cancer letters·2024
Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011
Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010
See all related articles

Cancer vaccine development is advancing, drawing parallels with infectious disease vaccines but facing challenges like immune evasion. Early clinical data, though limited, show encouraging signs of efficacy for novel cancer vaccination strategies.

Area of Science:

  • Oncology
  • Immunology
  • Vaccinology

Background:

  • Cancer vaccine development has seen rapid preclinical and technological advancements.
  • The field parallels infectious disease vaccination but faces unique challenges, including immune evasion and treating established disease.

Purpose of the Study:

  • To review the progress and current state of clinical cancer vaccine applications.
  • To highlight the evolution of cancer vaccine strategies and their associated challenges.

Main Methods:

  • Review of initial whole irradiated tumor cell vaccines.
  • Exploration of refined approaches using tumor antigens, subunits, and various delivery systems (dendritic cells, DNA, RNA, viral vectors).
  • Consideration of immune system modulation, including boosting and conditioning.

Related Experiment Videos

Main Results:

  • Initial whole tumor cell vaccines show some success.
  • Refined methods utilizing tumor antigens and advanced delivery systems are under investigation.
  • Limited clinical efficacy data are emerging and considered encouraging.

Conclusions:

  • Despite challenges, cancer vaccination research is progressing steadily.
  • Optimizing immune responses through boosting and conditioning is crucial for efficacy.
  • Diverse research avenues are being pursued, with mainstream approaches yet to be established.